[go: up one dir, main page]

GB202108181D0 - New formulation - Google Patents

New formulation

Info

Publication number
GB202108181D0
GB202108181D0 GBGB2108181.5A GB202108181A GB202108181D0 GB 202108181 D0 GB202108181 D0 GB 202108181D0 GB 202108181 A GB202108181 A GB 202108181A GB 202108181 D0 GB202108181 D0 GB 202108181D0
Authority
GB
United Kingdom
Prior art keywords
new formulation
formulation
new
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GBGB2108181.5A
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Diomed Developments Ltd
Original Assignee
Diomed Developments Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Diomed Developments Ltd filed Critical Diomed Developments Ltd
Priority to GBGB2108181.5A priority Critical patent/GB202108181D0/en
Publication of GB202108181D0 publication Critical patent/GB202108181D0/en
Priority to US18/031,296 priority patent/US20230372324A1/en
Priority to PCT/EP2021/077016 priority patent/WO2022078772A1/en
Priority to EP21790391.3A priority patent/EP4228641A1/en
Ceased legal-status Critical Current

Links

GBGB2108181.5A 2020-10-13 2021-06-08 New formulation Ceased GB202108181D0 (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
GBGB2108181.5A GB202108181D0 (en) 2021-06-08 2021-06-08 New formulation
US18/031,296 US20230372324A1 (en) 2020-10-13 2021-09-30 Gel formulations comprising montelukast
PCT/EP2021/077016 WO2022078772A1 (en) 2020-10-13 2021-09-30 Gel formulations comprising montelukast
EP21790391.3A EP4228641A1 (en) 2020-10-13 2021-09-30 Gel formulations comprising montelukast

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB2108181.5A GB202108181D0 (en) 2021-06-08 2021-06-08 New formulation

Publications (1)

Publication Number Publication Date
GB202108181D0 true GB202108181D0 (en) 2021-07-21

Family

ID=76838698

Family Applications (1)

Application Number Title Priority Date Filing Date
GBGB2108181.5A Ceased GB202108181D0 (en) 2020-10-13 2021-06-08 New formulation

Country Status (1)

Country Link
GB (1) GB202108181D0 (en)

Similar Documents

Publication Publication Date Title
IL284688A (en) Formulation
GB202007546D0 (en) Formulation
GB201913232D0 (en) Aerosolisable formulation
CA3265980A1 (en) Upadacitinib formulation
IL307849A (en) Sotorasib formulation
GB202102636D0 (en) Formulation
GB2599912B (en) New formulation
GB202115303D0 (en) New formulation
GB202108181D0 (en) New formulation
IL308046A (en) Alpelisib formulation
GB202108165D0 (en) Formulation
GB202107439D0 (en) Formulation
GB202107203D0 (en) Formulation
PL4138585T3 (en) Aerosolisable formulation
GB202103970D0 (en) Formulation
GB202102408D0 (en) Formulation
GB202016274D0 (en) Formulation
IL305977A (en) Formulation comprising ceralasertib
GB202010573D0 (en) Formulation
GB202005340D0 (en) Formulation
GB202003048D0 (en) Formulation
GB2595301B (en) Novel Formulation
GB2595300B (en) Novel Formulation
GB2595453B (en) Novel Formulation
CA3265602A1 (en) Aerosolisable formulation

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)